Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 61

1.

How to manage lymph nodes in ovarian cancer.

Harter P, Heitz F, Ataseven B, Schneider S, Baert T, Prader S, du Bois A.

Cancer. 2019 Dec 15;125 Suppl 24:4573-4577. doi: 10.1002/cncr.32514. Review.

PMID:
31967675
2.

Human leucocyte antigen class I in hormone receptor-positive, HER2-negative breast cancer: association with response and survival after neoadjuvant chemotherapy.

Sinn BV, Weber KE, Schmitt WD, Fasching PA, Symmans WF, Blohmer JU, Karn T, Taube ET, Klauschen F, Marmé F, Schem C, Stickeler E, Ataseven B, Huober J, von Minckwitz G, Seliger B, Denkert C, Loibl S.

Breast Cancer Res. 2019 Dec 11;21(1):142. doi: 10.1186/s13058-019-1231-z.

3.

Perception of side effects associated with anticancer treatment in women with breast or ovarian cancer (KEM-GO-1): a prospective trial.

Ataseven B, Frindte J, Harter P, Gebers G, Vogt C, Traut A, Breit E, Bluni V, Reinisch M, Heitz F, Kostara A, Kuemmel S, Prader S, Bommert M, Schneider S, du Bois A.

Support Care Cancer. 2019 Dec 11. doi: 10.1007/s00520-019-05216-y. [Epub ahead of print]

PMID:
31828488
4.

Impact of Nuclear Oestrogen Receptor Beta Expression in Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy.

Heitz F, Kümmel S, Lederer B, Solbach C, Engels K, Ataseven B, Sinn B, Blohmer JU, Denkert C, Barinoff J, Fisseler-Eckhoff A, Loibl S.

Geburtshilfe Frauenheilkd. 2019 Oct;79(10):1110-1117. doi: 10.1055/a-0987-9898. Epub 2019 Oct 22.

5.

Dilution of Molecular-Pathologic Gene Signatures by Medically Associated Factors Might Prevent Prediction of Resection Status After Debulking Surgery in Patients With Advanced Ovarian Cancer.

Heitz F, Kommoss S, Tourani R, Grandelis A, Uppendahl L, Aliferis C, Burges A, Wang C, Canzler U, Wang J, Belau A, Prader S, Hanker L, Ma S, Ataseven B, Hilpert F, Schneider S, Sehouli J, Kimmig R, Kurzeder C, Schmalfeldt B, Braicu EI, Harter P, Dowdy SC, Winterhoff BJ, Pfisterer J, du Bois A.

Clin Cancer Res. 2020 Jan 1;26(1):213-219. doi: 10.1158/1078-0432.CCR-19-1741. Epub 2019 Sep 16.

PMID:
31527166
6.

Post-Mastectomy Radiotherapy After Neoadjuvant Chemotherapy in Breast Cancer: A Pooled Retrospective Analysis of Three Prospective Randomized Trials.

Krug D, Lederer B, Seither F, Nekljudova V, Ataseven B, Blohmer JU, Costa SD, Denkert C, Ditsch N, Gerber B, Hanusch C, Heil J, Hilfrich J, Huober JB, Jackisch C, Kümmel S, Paepke S, Schem C, Schneeweiss A, Untch M, Debus J, von Minckwitz G, Kühn T, Loibl S.

Ann Surg Oncol. 2019 Nov;26(12):3892-3901. doi: 10.1245/s10434-019-07635-x. Epub 2019 Jul 26.

PMID:
31350646
7.

Updated Survival Analysis after a Median Follow-up of 12 Years of an Anthracycline-Containing Adjuvant Prospective Multicentre, Randomised Phase III Trial on Dose-Dense Chemotherapy in Primary Node-Positive, High-Risk Breast Cancer Patients.

Reinisch M, Gluz O, Ataseven B, Blohmer JU, Budner M, Dittmer-Grabowski C, Kohls A, Krocker J, Kümmel A, Hagemann F, Rüland A, Traut A, Kümmel S.

Breast Care (Basel). 2019 Jun;14(3):159-164. doi: 10.1159/000491792. Epub 2018 Sep 5.

8.

Hypoglossal acupuncture for acute chemotherapy-induced dysgeusia in patients with breast cancer: study protocol of a randomized, sham-controlled trial.

Haller H, Wang T, Lauche R, Choi KE, Voiß P, Felber S, Cramer H, Ataseven B, Kümmel S, Paul A, Dobos G.

Trials. 2019 Jul 4;20(1):398. doi: 10.1186/s13063-019-3525-y.

9.

Low anterior resection syndrome (LARS) in patients with epithelial ovarian cancer after primary debulking surgery.

Kranawetter M, Ataseven B, Grimm C, Schneider S, Riss S, Alesina P, Prader S, Walz MK, Harpain F, Stift A, Heitz F, Reinthaller A, Polterauer S, Harter P, du Bois A.

Gynecol Oncol. 2019 Sep;154(3):577-582. doi: 10.1016/j.ygyno.2019.06.015. Epub 2019 Jun 21.

PMID:
31235241
10.

Clinical and analytical validation of Ki-67 in 9069 patients from IBCSG VIII + IX, BIG1-98 and GeparTrio trial: systematic modulation of interobserver variance in a comprehensive in silico ring trial.

Denkert C, Budczies J, Regan MM, Loibl S, Dell'Orto P, von Minckwitz G, Mastropasqua MG, Solbach C, Thürlimann B, Mehta K, Blohmer JU, Colleoni M, Müller V, Klauschen F, Ataseven B, Engels K, Kammler R, Pfitzner BM, Dietel M, Fasching PA, Viale G.

Breast Cancer Res Treat. 2019 Aug;176(3):557-568. doi: 10.1007/s10549-018-05112-9. Epub 2019 May 7.

PMID:
31065870
11.

Benchmarking of a checklist for the identification of familial risk for breast and ovarian cancers in a prospective cohort.

Rhiem K, Bücker-Nott HJ, Hellmich M, Fischer H, Ataseven B, Dittmer-Grabowski C, Latos K, Pelzer V, Seifert M, Schmidt A, Rezek D, Groh U, Meinerz W, Crommelinck D, Hahnen E, Wesselmann S, Schmutzler RK.

Breast J. 2019 May;25(3):455-460. doi: 10.1111/tbj.13257. Epub 2019 Apr 5.

PMID:
30953388
12.

Validation of a Nomogram Predicting Non-Sentinel Lymph Node Metastases among Patients with Breast Cancer after Primary Systemic Therapy - a transSENTINA Substudy.

Liedtke C, Görlich D, Bauerfeind I, Fehm T, Fleige B, Helms G, Lebeau A, Staebler A, Ataseven B, Denkert C, Gerber B, Heil J, Krug D, Kümmel S, Schwentner L, von Minckwitz G, Loibl S, Untch M, Kühn T.

Breast Care (Basel). 2018 Dec;13(6):440-446. doi: 10.1159/000489565. Epub 2018 Nov 6.

13.

Pattern and impact of metastatic cardiophrenic lymph nodes in advanced epithelial ovarian cancer.

Prader S, Vollmar N, du Bois A, Heitz F, Schneider S, Ataseven B, Bommert M, Waltering KU, Heikaus S, Koch JA, Alesina PF, Traut A, Harter P.

Gynecol Oncol. 2019 Jan;152(1):76-81. doi: 10.1016/j.ygyno.2018.11.001. Epub 2018 Nov 18.

PMID:
30463683
14.

Low-grade Serous Ovarian Carcinoma.

Ricciardi E, Baert T, Ataseven B, Heitz F, Prader S, Bommert M, Schneider S, du Bois A, Harter P.

Geburtshilfe Frauenheilkd. 2018 Oct;78(10):972-976. doi: 10.1055/a-0717-5411. Epub 2018 Oct 19.

15.

Diagnosis of Li-Fraumeni Syndrome: Differentiating TP53 germline mutations from clonal hematopoiesis: Results of the observational AGO-TR1 trial.

Weber-Lassalle K, Harter P, Hauke J, Ernst C, Kommoss S, Marmé F, Weber-Lassalle N, Prieske K, Dietrich D, Borde J, Pohl-Rescigno E, Reuss A, Ataseven B, Engel C, Stingl JC, Schmutzler RK, Hahnen E.

Hum Mutat. 2018 Dec;39(12):2040-2046. doi: 10.1002/humu.23653. Epub 2018 Oct 3.

PMID:
30216591
16.

Skeletal Muscle Attenuation (Sarcopenia) Predicts Reduced Overall Survival in Patients with Advanced Epithelial Ovarian Cancer Undergoing Primary Debulking Surgery.

Ataseven B, Luengo TG, du Bois A, Waltering KU, Traut A, Heitz F, Alesina PF, Prader S, Meier B, Schneider S, Koch JA, Walz M, Groeben HT, Nina P, Brunkhorst V, Heikaus S, Harter P.

Ann Surg Oncol. 2018 Oct;25(11):3372-3379. doi: 10.1245/s10434-018-6683-3. Epub 2018 Aug 1.

PMID:
30069659
17.

Adjuvant Subcutaneous Trastuzumab for HER2-Positive Early Breast Cancer: Subgroup Analyses of Safety and Active Medical Conditions by Body Weight in the SafeHer Phase III Study.

Jung KH, Ataseven B, Verrill M, Pivot X, De Laurentiis M, Al-Sakaff N, Lauer S, Shing M, Gligorov J, Azim HA.

Oncologist. 2018 Oct;23(10):1137-1143. doi: 10.1634/theoncologist.2018-0065. Epub 2018 Jul 17.

18.

Stage- and Histologic Subtype-Dependent Frequency of Lymph Node Metastases in Patients with Epithelial Ovarian Cancer Undergoing Systematic Pelvic and Paraaortic Lymphadenectomy.

Heitz F, Harter P, Ataseven B, Heikaus S, Schneider S, Prader S, Bommert M, Fisseler-Eckhoff A, Traut A, du Bois A.

Ann Surg Oncol. 2018 Jul;25(7):2053-2059. doi: 10.1245/s10434-018-6412-y. Epub 2018 Apr 9.

PMID:
29633097
19.

Prognostic Value of the Age-Adjusted Charlson Comorbidity Index (ACCI) on Short- and Long-Term Outcome in Patients with Advanced Primary Epithelial Ovarian Cancer.

Kahl A, du Bois A, Harter P, Prader S, Schneider S, Heitz F, Traut A, Alesina PF, Meier B, Walz M, Brueckner A, Groeben HT, Brunkhorst V, Heikaus S, Ataseven B.

Ann Surg Oncol. 2017 Nov;24(12):3692-3699. doi: 10.1245/s10434-017-6079-9. Epub 2017 Sep 5.

PMID:
28871563
20.

Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients.

Gligorov J, Ataseven B, Verrill M, De Laurentiis M, Jung KH, Azim HA, Al-Sakaff N, Lauer S, Shing M, Pivot X; SafeHer Study Group.

Eur J Cancer. 2017 Sep;82:237-246. doi: 10.1016/j.ejca.2017.05.010. Epub 2017 Jun 16.

PMID:
28625777
21.

The impact of type and number of bowel resections on anastomotic leakage risk in advanced ovarian cancer surgery.

Grimm C, Harter P, Alesina PF, Prader S, Schneider S, Ataseven B, Meier B, Brunkhorst V, Hinrichs J, Kurzeder C, Heitz F, Kahl A, Traut A, Groeben HT, Walz M, du Bois A.

Gynecol Oncol. 2017 Sep;146(3):498-503. doi: 10.1016/j.ygyno.2017.06.007. Epub 2017 Jun 10.

PMID:
28610745
22.

Serous Tubal Intraepithelial Carcinoma Associated With Extraovarian Metastases.

Schneider S, Heikaus S, Harter P, Heitz F, Grimm C, Ataseven B, Prader S, Kurzeder C, Ebel T, Traut A, du Bois A.

Int J Gynecol Cancer. 2017 Mar;27(3):444-451. doi: 10.1097/IGC.0000000000000920.

PMID:
28187099
23.
24.

Using ultrasound and palpation for predicting axillary lymph node status following neoadjuvant chemotherapy - Results from the multi-center SENTINA trial.

Schwentner L, Helms G, Nekljudova V, Ataseven B, Bauerfeind I, Ditsch N, Fehm T, Fleige B, Hauschild M, Heil J, Kümmel S, Lebeau A, Schmatloch S, Schrenk P, Staebler A, Loibl S, Untch M, Von Minckwitz G, Liedtke C, Kühn T.

Breast. 2017 Feb;31:202-207. doi: 10.1016/j.breast.2016.11.012. Epub 2016 Nov 24.

PMID:
27889596
25.

Intake of selective beta blockers has no impact on survival in patients with epithelial ovarian cancer.

Heitz F, Hengsbach A, Harter P, Traut A, Ataseven B, Schneider S, Prader S, Kurzeder C, Sporkmann M, du Bois A.

Gynecol Oncol. 2017 Jan;144(1):181-186. doi: 10.1016/j.ygyno.2016.11.012. Epub 2016 Nov 16.

PMID:
27863705
26.

Impact of Abdominal Wall Metastases on Prognosis in Epithelial Ovarian Cancer.

Ataseven B, du Bois A, Harter P, Prader S, Grimm C, Kurzeder C, Schneider S, Heikaus S, Kahl A, Traut A, Heitz F.

Int J Gynecol Cancer. 2016 Nov;26(9):1594-1600.

PMID:
27654263
27.

Prognostic Impact of Port-Site Metastasis After Diagnostic Laparoscopy for Epithelial Ovarian Cancer.

Ataseven B, Grimm C, Harter P, Heikaus S, Heitz F, Traut A, Prader S, Kahl A, Schneider S, Kurzeder C, du Bois A.

Ann Surg Oncol. 2016 Dec;23(Suppl 5):834-840. Epub 2016 Jul 12.

PMID:
27406097
28.

The Impact of Neoadjuvant Treatment on Surgical Options and Outcomes.

Ataseven B, von Minckwitz G.

Ann Surg Oncol. 2016 Oct;23(10):3093-9. doi: 10.1245/s10434-016-5364-3. Epub 2016 Jun 30. Review.

PMID:
27364505
29.

FIGO stage IV epithelial ovarian, fallopian tube and peritoneal cancer revisited.

Ataseven B, Chiva LM, Harter P, Gonzalez-Martin A, du Bois A.

Gynecol Oncol. 2016 Sep;142(3):597-607. doi: 10.1016/j.ygyno.2016.06.013. Epub 2016 Jun 19. Review.

PMID:
27335253
30.

The revised 2014 FIGO staging system for epithelial ovarian cancer: Is a subclassification into FIGO stage IVA and IVB justified?

Ataseven B, Harter P, Grimm C, Heitz F, Heikaus S, Traut A, Kahl A, Kurzeder C, Prader S, du Bois A.

Gynecol Oncol. 2016 Aug;142(2):243-7. doi: 10.1016/j.ygyno.2016.05.021. Epub 2016 May 25.

PMID:
27208538
31.

Neoadjuvant Dose-Dense and Dose-Intensified Chemotherapy in Breast Cancer - Review of the Literature.

Reinisch M, Ataseven B, Kümmel S.

Breast Care (Basel). 2016 Feb;11(1):13-20. doi: 10.1159/000444543. Epub 2016 Feb 23. Review.

32.

Pattern of and reason for postoperative residual disease in patients with advanced ovarian cancer following upfront radical debulking surgery.

Heitz F, Harter P, Alesina PF, Walz MK, Lorenz D, Groeben H, Heikaus S, Fisseler-Eckhoff A, Schneider S, Ataseven B, Kurzeder C, Prader S, Beutel B, Traut A, du Bois A.

Gynecol Oncol. 2016 May;141(2):264-270. doi: 10.1016/j.ygyno.2016.03.015. Epub 2016 Mar 24.

PMID:
26975900
33.

Surgical management of cardiophrenic lymph nodes in patients with advanced ovarian cancer.

Prader S, Harter P, Grimm C, Traut A, Waltering KU, Alesina PF, Heikaus S, Ataseven B, Heitz F, Schneider S, du Bois A.

Gynecol Oncol. 2016 May;141(2):271-275. doi: 10.1016/j.ygyno.2016.03.012. Epub 2016 Mar 17.

PMID:
26972337
34.

Prognostic impact of debulking surgery and residual tumor in patients with epithelial ovarian cancer FIGO stage IV.

Ataseven B, Grimm C, Harter P, Heitz F, Traut A, Prader S, du Bois A.

Gynecol Oncol. 2016 Feb;140(2):215-20. doi: 10.1016/j.ygyno.2015.12.007. Epub 2015 Dec 12.

PMID:
26691222
35.

Diagnosis of pathological complete response to neoadjuvant chemotherapy in breast cancer by minimal invasive biopsy techniques.

Heil J, Kümmel S, Schaefgen B, Paepke S, Thomssen C, Rauch G, Ataseven B, Große R, Dreesmann V, Kühn T, Loibl S, Blohmer JU, von Minckwitz G.

Br J Cancer. 2015 Dec 1;113(11):1565-70. doi: 10.1038/bjc.2015.381. Epub 2015 Nov 10.

36.

Prognostic Factors for Local, Loco-regional and Systemic Recurrence in Early-stage Breast Cancer.

Kümmel A, Kümmel S, Barinoff J, Heitz F, Holtschmidt J, Weikel W, Lorenz-Salehi F, du Bois A, Harter P, Traut A, Blohmer JU, Ataseven B.

Geburtshilfe Frauenheilkd. 2015 Jul;75(7):710-718.

37.

Subcutaneous Trastuzumab for HER2-positive Breast Cancer - Evidence and Practical Experience in 7 German Centers.

Jackisch C, Müller V, Dall P, Neumeister R, Park-Simon TW, Ruf-Dördelmann A, Seiler S, Tesch H, Ataseven B.

Geburtshilfe Frauenheilkd. 2015 Jun;75(6):566-573. Review.

38.

Pre-operative serum albumin is associated with post-operative complication rate and overall survival in patients with epithelial ovarian cancer undergoing cytoreductive surgery.

Ataseven B, du Bois A, Reinthaller A, Traut A, Heitz F, Aust S, Prader S, Polterauer S, Harter P, Grimm C.

Gynecol Oncol. 2015 Sep;138(3):560-5. doi: 10.1016/j.ygyno.2015.07.005. Epub 2015 Jul 8.

PMID:
26163893
39.

Sequential Salinomycin Treatment Results in Resistance Formation through Clonal Selection of Epithelial-Like Tumor Cells.

Kopp F, Hermawan A, Oak PS, Ulaganathan VK, Herrmann A, Elnikhely N, Thakur C, Xiao Z, Knyazev P, Ataseven B, Savai R, Wagner E, Roidl A.

Transl Oncol. 2014 Dec;7(6):702-11. doi: 10.1016/j.tranon.2014.09.002.

40.

Additional prognostic value of lymph node ratio over pN staging in different breast cancer subtypes based on the results of 1,656 patients.

Ataseven B, Kümmel S, Weikel W, Heitz F, Holtschmidt J, Lorenz-Salehi F, Kümmel A, Traut A, Blohmer J, Harter P, du Bois A.

Arch Gynecol Obstet. 2015 May;291(5):1153-66. doi: 10.1007/s00404-014-3528-6. Epub 2014 Nov 5.

PMID:
25367604
41.

Expression of secreted protein acidic and rich in cysteine (SPARC) in breast cancer and response to neoadjuvant chemotherapy.

Lindner JL, Loibl S, Denkert C, Ataseven B, Fasching PA, Pfitzner BM, Gerber B, Gade S, Darb-Esfahani S, Sinn BV, Huober J, Engels K, Tesch H, Karn T, Pommerenke F, Liedtke C, Untch M, Müller V, Rack B, Schem C, von Minckwitz G.

Ann Oncol. 2015 Jan;26(1):95-100. doi: 10.1093/annonc/mdu487. Epub 2014 Oct 29.

PMID:
25355716
42.

PTK7 as a potential prognostic and predictive marker of response to adjuvant chemotherapy in breast cancer patients, and resistance to anthracycline drugs.

Ataseven B, Gunesch A, Eiermann W, Kates RE, Högel B, Knyazev P, Ullrich A, Harbeck N.

Onco Targets Ther. 2014 Oct 6;7:1723-31. doi: 10.2147/OTT.S62676. eCollection 2014.

43.

Prognostic value of lymph node ratio in patients with advanced epithelial ovarian cancer.

Ataseven B, Grimm C, Harter P, Prader S, Traut A, Heitz F, du Bois A.

Gynecol Oncol. 2014 Dec;135(3):435-40. doi: 10.1016/j.ygyno.2014.10.003. Epub 2014 Oct 12.

PMID:
25312398
44.

Impact of multifocal or multicentric disease on surgery and locoregional, distant and overall survival of 6,134 breast cancer patients treated with neoadjuvant chemotherapy.

Ataseven B, Lederer B, Blohmer JU, Denkert C, Gerber B, Heil J, Kühn T, Kümmel S, Rezai M, Loibl S, von Minckwitz G.

Ann Surg Oncol. 2015 Apr;22(4):1118-27. doi: 10.1245/s10434-014-4122-7. Epub 2014 Oct 9.

PMID:
25297900
45.

Subcutaneous Administration of Monoclonal Antibodies in Oncology.

Jackisch C, Müller V, Maintz C, Hell S, Ataseven B.

Geburtshilfe Frauenheilkd. 2014 Apr;74(4):343-349.

46.

Gross cystic disease fluid protein 15 (GCDFP-15) expression in breast cancer subtypes.

Darb-Esfahani S, von Minckwitz G, Denkert C, Ataseven B, Högel B, Mehta K, Kaltenecker G, Rüdiger T, Pfitzner B, Kittel K, Fiedler B, Baumann K, Moll R, Dietel M, Eidtmann H, Thomssen C, Loibl S.

BMC Cancer. 2014 Jul 28;14:546. doi: 10.1186/1471-2407-14-546.

47.

PTK 7 is a transforming gene and prognostic marker for breast cancer and nodal metastasis involvement.

Gärtner S, Gunesch A, Knyazeva T, Wolf P, Högel B, Eiermann W, Ullrich A, Knyazev P, Ataseven B.

PLoS One. 2014 Jan 7;9(1):e84472. doi: 10.1371/journal.pone.0084472. eCollection 2014.

48.

PTK7 expression in triple-negative breast cancer.

Ataseven B, Angerer R, Kates R, Gunesch A, Knyazev P, Högel B, Becker C, Eiermann W, Harbeck N.

Anticancer Res. 2013 Sep;33(9):3759-63.

PMID:
24023307
49.

Predictive value of sphingosine kinase 1 expression in neoadjuvant treatment of breast cancer.

Ruckhäberle E, Karn T, Denkert C, Loibl S, Ataseven B, Reimer T, Becker S, Holtrich U, Rody A, Darb-Esfahani S, Nekljudova V, von Minckwitz G.

J Cancer Res Clin Oncol. 2013 Oct;139(10):1681-9. doi: 10.1007/s00432-013-1490-5. Epub 2013 Aug 18.

PMID:
23955546
50.

Monocytes/macrophages support mammary tumor invasivity by co-secreting lineage-specific EGFR ligands and a STAT3 activator.

Vlaicu P, Mertins P, Mayr T, Widschwendter P, Ataseven B, Högel B, Eiermann W, Knyazev P, Ullrich A.

BMC Cancer. 2013 Apr 18;13:197. doi: 10.1186/1471-2407-13-197.

Supplemental Content

Loading ...
Support Center